Another Vaccine Candidate Joins Operation Warp Speed

The United States reached a deal for up to $2.1 billion with pharmaceutical firms Sanofi and GlaxoSmithKline, for the development and (if it is effective) production of up to 100 million doses of a potential COVID-19 vaccine, based on proteins found on SARS-CoV-2. Sanofi’s effort is now a part of Operation Warp Speed, joining the Pfizer-BioNTech, AstraZeneca-University of Oxford, and Novavax Inc. vaccines, as well as the Regeneron antibody treatment.